Autonomix Medical Inc Stock Price, News & Analysis

Autonomix Medical (NASDAQ: AMIX) has been granted U.S. Patent No. 12,257,071 for its innovative catheter-based platform technology. The patent covers advanced systems combining nerve mapping and radiofrequency (RF) ablation technologies for treating nerve-related conditions. Key features include deployable microfingers with embedded sensors, real-time physiological monitoring, and adaptive modulation capabilities.

The technology utilizes a catheter-based microchip sensing array antenna that can detect and differentiate neural signals with enhanced sensitivity compared to existing solutions. The company's portfolio now includes over 80 issued patents and 40 pending applications. Autonomix plans to submit an Investigational Device Exemption (IDE) and begin U.S. clinical trials in 2025 for treating pancreatic cancer pain.

Autonomix Medical (NASDAQ: AMIX) announced its participation in the Virtual Investor Closing Bell Series scheduled for May 22, 2025, at 4:00 PM ET. During the event, CEO Brad Hauser will provide a corporate overview and discuss the company's innovative catheter-based microchip sensing array technology. This first-in-class platform system aims to enhance neural signal detection and differentiation compared to existing technologies.

The event will include a live interactive Q&A session where investors can submit questions. The presentation will be accessible through a live video webcast on the company's website, with a replay available for 90 days following the event.

Autonomix Medical (NASDAQ: AMIX) has announced plans to initiate a follow-on expansion study (PoC 2) in Q2 2025, following positive results from their initial proof-of-concept trial (PoC 1) for pancreatic cancer pain treatment. The PoC 2 phase will expand testing to include gall bladder, liver, and bile duct cancers, potentially doubling the company's addressable market.

The PoC 1 trial demonstrated significant pain reduction, decreased opioid use, and improved quality of life in late-stage pancreatic cancer patients. The company's smart catheter technology platform shows promise for various applications, including cardiology, hypertension, and chronic pain management. The technology focuses on delivering transvascular energy to ablate problematic nerves for pain mitigation.

Autonomix Medical (NASDAQ: AMIX) has released compelling patient testimonial results from its first-in-human proof-of-concept trial evaluating transvascular nerve ablation for pancreatic cancer pain. The study, which enrolled 20 patients, demonstrated statistically significant pain relief within 24 hours of the procedure.

Key results include: 53.3% pain improvement at 7 days post-procedure (mean pain reduction from 7.81 to 3.65 on VAS scale) and 59.2% improvement at 4-6 weeks (reduction from 7.89 to 3.22). Notably, 100% of responding patients eliminated opioid use at 7 days post-procedure, with 73% remaining opioid-free at 4-6 weeks. The procedure showed a strong safety profile with no serious adverse events.

Based on these positive outcomes, Autonomix is expanding its protocol into PoC 2 phase, including pain management for additional visceral cancers and earlier-stage pancreatic cancer patients.

Autonomix Medical (NASDAQ: AMIX) has participated in a Virtual Investor "What This Means" segment featuring Chief Medical Officer Dr. Robert Schwartz. The discussion focused on two key aspects: the successful completion of their initial first-in-human proof-of-concept trial (PoC 1), which demonstrated meaningful pain reduction, and their plans for a market expansion study (PoC 2). The PoC 2 trial, scheduled to begin in Q2 2025, will evaluate their technology's effectiveness in treating pain across additional visceral cancers and earlier-stage pancreatic cancer. The company's technology focuses on using transvascular energy to ablate problematic nerves for pain mitigation in cancer patients.

Autonomix Medical reports positive outcomes from its first-in-human proof-of-concept trial for pancreatic cancer pain treatment. The study enrolled 20 patients, with 19 receiving treatment through their innovative nerve ablation technology.

Key results include:

• 100% of femoral access patients responded to treatment
• 43.6% pain improvement at 7 days post-procedure
• 49.7% pain improvement at 4-6 weeks
• 100% of responding patients achieved zero opioid use at 7 days
• 73% remained opioid-free at 4-6 weeks

Based on these successful outcomes, Autonomix is expanding its study (PoC 2) to include additional visceral cancers and earlier-stage pancreatic cancer patients. The company's technology shows potential beyond cancer pain management, with possible applications in cardiology, hypertension, and chronic pain management. The expanded trial will begin in Q2 2025.

Autonomix Medical (NASDAQ: AMIX) announced that its technology and early proof-of-concept study results will be showcased at EuroPCR, a leading interventional cardiovascular medicine conference in Paris, France from May 20-23, 2025.

The presentation, titled 'Catheter-Based Transvascular RF Neural Ablation For Severe Pancreatic Cancer Pain Elpis Study', will be featured during PCR Innovators Day. The company's Chief Medical Officer, Dr. Robert S. Schwartz, will be the presenting author of the poster, highlighting Autonomix's developments in precision nerve-targeted treatments.

Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in nervous system disease diagnosis and treatment technologies, has announced an inducement stock option grant. The grant, approved by the Company's Compensation Committee on April 17, 2025, allows a new non-executive employee to purchase 5,000 shares of common stock.

The option's exercise price matches Autonomix's closing price on the Nasdaq Capital Market on April 17, 2025. The grant features a ten-year term and vests in four equal annual installments, contingent upon the employee's continued employment with the company through the vesting dates. This grant was made under Nasdaq Rule 5635(c)(4) as part of the employee's compensation package.

Autonomix Medical (NASDAQ: AMIX) has been granted European Patent No. 3,226,792 for its catheter-based technology in neuromodulation. The patent covers methods and systems for nerve monitoring and surgical procedures related to regulating prostate and tumor growth.

The technology's applications include sensing, ablating, and verifying neurological traffic to the prostate and lower urinary tract (LUT) organs, with potential to treat conditions like chronic prostatitis, hypogonadism, nocturia, and erectile dysfunction. The company's patent portfolio now includes over 80 issued patents and 40 pending applications.

While primarily focused on developing treatments for pancreatic cancer pain by targeting the celiac plexus, Autonomix plans to submit an IDE and begin U.S. clinical trials in 2025 to commercialize their Sensing and RF Ablation System.